Compound comparison
A structured research comparison between Pinealon and Semax across compound identity, research category, evidence maturity, and interpretation boundaries.
Short peptide bioregulator
Proposed as a short peptide bioregulator; direct molecular targets and independent replication remain limited.
Preclinical foundation
The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.
ACTH-fragment-derived neuropeptide
Investigated across neurotrophic, transcriptional, and stress-response signaling; no single mechanism explains the full literature.
Early human evidence
The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.
| Dimension | Pinealon | Semax |
|---|---|---|
| Catalog identity | Pinealon is mapped to short peptide bioregulator research. | Semax is mapped to ACTH-fragment-derived neuropeptide research. |
| Research category | Pinealon is primarily organized around aging, cognition, and bioregulator models. | Semax is primarily organized around neuroprotection and cognition research. |
| Interpretive boundary | Use the Pinealon profile and verified study pages before inferring mechanism or outcomes. | Use the Semax profile and verified study pages before inferring mechanism or outcomes. |
Comparison pages organize differences; they do not establish superiority, equivalence, or individual suitability.
Short peptide bioregulator literature index
PubMed, U.S. National Library of Medicine · Database
Atlas internal research database
Internal Research Database · 2026 · Database
Semax literature index
PubMed, U.S. National Library of Medicine · Database
Continue the research map
